Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific LCT ENSG00000115850 Lactase 2 135787840-135837180 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA007408 Uncertain Not detected Group enriched 640 duodenum: 229.4;small intestine: 146.2 appendix,breast,lymph node,testis: 0.2 DEFA6 DEF6, HD-6 ENSG00000164822 Defensin, alpha 6, Paneth cell-specific 8 6924693-6926076 Plasma proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA019462 Supported Tissue enhanced Group enriched 521 duodenum: 5909.3;small intestine: 10744.7 colon: 15.9 DEFA5 DEF5, HD-5 ENSG00000164816 Defensin, alpha 5, Paneth cell-specific 8 7055304-7056734 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA015775, CAB069919 Supported Colorectal cancer:9.44e-5 (favourable) Tissue enhanced Group enriched 462 duodenum: 10985.4;small intestine: 19506.1 appendix: 33.0 CCL25 Ckb15, SCYA25, TECK ENSG00000131142 Chemokine (C-C motif) ligand 25 19 8052767-8062650 Predicted secreted proteins Evidence at protein level HPA055883 Uncertain Group enriched Group enriched 320 duodenum: 544.3;small intestine: 667.7 lymph node: 1.8 RBP2 CRABP-II, CRBP2, CRBPII, RBPC2 ENSG00000114113 Retinol binding protein 2, cellular 3 139452884-139480747 Predicted intracellular proteins, Transporters Evidence at protein level HPA035866 Supported Approved Golgi apparatus Tissue enhanced Group enriched 207 duodenum: 2824.3;small intestine: 2085.7 lung: 11.8 CYP3A4 CYP3A3 ENSG00000160868 Cytochrome P450, family 3, subfamily A, polypeptide 4 7 99756960-99784265 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB033671, HPA072245 Supported Uncertain Cytosol Tissue enriched Group enriched 200 duodenum: 849.6;liver: 2446.6;small intestine: 990.4 adrenal gland: 7.1 GIP ENSG00000159224 Gastric inhibitory polypeptide 17 48958554-48968596 Plasma proteins, Predicted secreted proteins Evidence at protein level CAB016729, HPA021612 Supported Tissue enriched Group enriched 155 duodenum: 268.7;small intestine: 96.7 stomach: 1.1 APOA4 ENSG00000110244 Apolipoprotein A-IV 11 116820700-116823306 Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA001352, HPA002549, CAB068250, CAB068251, CAB068252 Supported Approved Vesicles Tissue enriched Group enriched 129 duodenum: 2273.3;small intestine: 3513.5 liver: 22.3 APOB ENSG00000084674 Apolipoprotein B 2 21001429-21044073 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB016070, HPA049793 Supported Supported Vesicles
Cytosol Tissue enriched Group enriched 122 duodenum: 187.7;liver: 619.0;small intestine: 340.0 adipose tissue: 3.1 CREB3L3 CREB-H ENSG00000060566 CAMP responsive element binding protein 3-like 3 19 4153601-4173054 Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA040671, HPA056228 Supported Renal cancer:3.53e-6 (unfavourable) Tissue enriched Group enriched 104 duodenum: 248.3;liver: 61.3;small intestine: 284.6 colon: 1.9 MS4A10 CD20L7, MS4A9 ENSG00000172689 Membrane-spanning 4-domains, subfamily A, member 10 11 60785348-60801305 Predicted membrane proteins, Transporters Evidence at transcript level HPA014778 Uncertain Not detected Group enriched 93 duodenum: 76.3;small intestine: 97.7 parathyroid gland: 0.9 C17orf78 FLJ39647 ENSG00000278505 Chromosome 17 open reading frame 78 17 37375986-37392708 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level Group enriched Group enriched 75 duodenum: 101.8;small intestine: 51.9 testis: 1.0 REG3A HIP, PAP, PAP1, PBCGF, REG-III, REG3 ENSG00000172016 Regenerating islet-derived 3 alpha 2 79157003-79159753 Plasma proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA047894, HPA048334, HPA060705 Supported Approved Cytosol Tissue enhanced Group enriched 57 duodenum: 5795.6;small intestine: 8246.6 stomach: 122.9 MEP1A PPHA ENSG00000112818 Meprin A, alpha (PABA peptide hydrolase) 6 46793390-46839782 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB025163, HPA029416 Supported Tissue enriched Group enriched 41 colon: 120.0;duodenum: 290.0;rectum: 116.2;small intestine: 549.0 appendix: 6.5 ISX RAXLX ENSG00000175329 Intestine-specific homeobox 22 35066136-35087387 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA060328 Approved Supported Nucleoplasm
Nuclear bodies Tissue enhanced Group enriched 37 colon: 27.9;duodenum: 38.5;rectum: 28.6;small intestine: 30.3 smooth muscle: 0.8 TM4SF20 FLJ22800, TCCE518 ENSG00000168955 Transmembrane 4 L six family member 20 2 227362156-227381995 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051838, HPA063184, HPA065531 Uncertain Supported Plasma membrane
Focal adhesion sites Group enriched Group enriched 36 duodenum: 285.0;small intestine: 167.3 testis: 6.3 MEP1B ENSG00000141434 Meprin A, beta 18 32185069-32220404 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029119 Supported Group enriched Group enriched 34 duodenum: 258.3;small intestine: 410.0 colon: 9.9 TM4SF4 il-TMP ENSG00000169903 Transmembrane 4 L six family member 4 3 149473974-149503281 Predicted membrane proteins, Transporters Evidence at protein level HPA046430 Supported Approved Plasma membrane
Cytosol Group enriched Group enriched 34 duodenum: 595.8;gallbladder: 1326.5;liver: 343.7;small intestine: 515.2 stomach: 20.3 UGT1A1 GNT1, UGT1, UGT1A ENSG00000241635 UDP glucuronosyltransferase 1 family, polypeptide A1 2 233760248-233773299 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level Tissue enriched Group enriched 33 duodenum: 205.0;liver: 155.7;small intestine: 83.9 kidney: 4.4 ABCG5 STSL ENSG00000138075 ATP-binding cassette, sub-family G (WHITE), member 5 2 43812472-43838865 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA016514 Approved Approved Nucleus Liver cancer:2.60e-5 (favourable) Tissue enriched Group enriched 32 duodenum: 58.0;liver: 28.3;small intestine: 57.4 gallbladder: 1.4 SLC10A2 ASBT, ISBT ENSG00000125255 Solute carrier family 10 (sodium/bile acid cotransporter), member 2 13 103043998-103066846 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA004795 Approved Renal cancer:5.78e-5 (favourable) Tissue enriched Group enriched 32 duodenum: 21.6;kidney: 15.3;small intestine: 52.2 gallbladder: 0.9 ALPI ENSG00000163295 Alkaline phosphatase, intestinal 2 232456123-232460032 Enzymes, Predicted secreted proteins Evidence at protein level HPA038764, HPA038765, HPA051699 Supported Approved Plasma membrane Tissue enhanced Group enriched 31 duodenum: 208.8;small intestine: 216.4 colon: 6.8 MUC6 ENSG00000184956 Mucin 6, oligomeric mucus/gel-forming 11 1012821-1036706 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB002165 Supported Tissue enhanced Group enriched 31 duodenum: 26.7;seminal vesicle: 71.3;stomach: 37.8 cervix, uterine,epididymis: 1.4 TFF2 SML1 ENSG00000160181 Trefoil factor 2 21 42346357-42351128 Cancer-related genes, Predicted secreted proteins Evidence at protein level CAB025834, HPA036705 Supported Liver cancer:1.99e-4 (unfavourable) Group enriched Group enriched 29 duodenum: 1057.0;stomach: 5161.6 gallbladder: 107.8 TBX10 TBX13, TBX7 ENSG00000167800 T-box 10 11 67631303-67639560 Predicted secreted proteins, Transcription factors Evidence at protein level HPA047881 Uncertain Group enriched Group enriched 27 colon: 9.0;duodenum: 6.0;rectum: 8.8;small intestine: 10.8 appendix,testis: 0.3 SLC28A1 CNT1 ENSG00000156222 Solute carrier family 28 (concentrative nucleoside transporter), member 1 15 84884654-84945796 Predicted membrane proteins, Transporters Evidence at protein level HPA019551 Supported Group enriched Group enriched 26 duodenum: 39.0;kidney: 49.1;liver: 35.4;small intestine: 54.7 placenta: 1.6 ABCG8 GBD4 ENSG00000143921 ATP-binding cassette, sub-family G (WHITE), member 8 2 43838964-43878466 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA019556 Uncertain Uncertain Vesicles Tissue enriched Group enriched 25 duodenum: 51.4;liver: 34.1;small intestine: 56.7 gallbladder: 1.8 BTNL3 BTN9.1, BTNLR ENSG00000168903 Butyrophilin-like 3 5 180988845-181006727 Predicted membrane proteins Evidence at transcript level Group enriched Group enriched 25 colon: 25.0;duodenum: 118.3;rectum: 26.8;small intestine: 90.9 gallbladder: 2.5 OTC ENSG00000036473 Ornithine carbamoyltransferase X 38352545-38421450 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA000243, HPA000570 Supported Supported Mitochondria Tissue enriched Group enriched 25 duodenum: 117.6;liver: 195.0;small intestine: 98.9 colon: 5.3 CEACAM20 UNQ9366 ENSG00000273777 Carcinoembryonic antigen-related cell adhesion molecule 20 19 44501677-44529788 Predicted membrane proteins Evidence at transcript level Group enriched Group enriched 24 duodenum: 39.9;prostate: 15.5;small intestine: 43.6 gallbladder: 1.3 CPS1 ENSG00000021826 Carbamoyl-phosphate synthase 1, mitochondrial 2 210477682-210679107 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB003781, HPA021400 Supported Approved Nucleoli Liver cancer:6.93e-5 (favourable) Tissue enriched Group enriched 24 duodenum: 241.2;liver: 697.3;small intestine: 147.2 testis: 15.2 ALDOB ENSG00000136872 Aldolase B, fructose-bisphosphate 9 101420578-101435823 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA002198, CAB020827 Supported Tissue enriched Group enriched 23 duodenum: 3808.7;kidney: 6531.8;liver: 5081.5;small intestine: 5731.3 gallbladder: 232.6 ENPP7 alk-SMase, NPP7 ENSG00000182156 Ectonucleotide pyrophosphatase/phosphodiesterase 7 17 79730919-79742222 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA024603 Approved Tissue enriched Group enriched 22 duodenum: 46.9;small intestine: 112.8 kidney: 3.5 ERICH4 C19orf69, LOC100170765 ENSG00000204978 Glutamate-rich 4 19 41443158-41444765 Predicted intracellular proteins Evidence at transcript level HPA042632, HPA048484 Uncertain Approved Nucleoplasm
Cytosol Mixed Group enriched 22 duodenum: 44.1;kidney: 16.2;small intestine: 43.8 lung: 1.6 APOBEC1 APOBEC-1, BEDP, CDAR1, HEPR ENSG00000111701 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 12 7649400-7665903 Enzymes, Predicted intracellular proteins Evidence at protein level Group enriched Group enriched 21 duodenum: 32.8;small intestine: 31.7 stomach: 1.5 C6orf58 ENSG00000184530 Chromosome 6 open reading frame 58 6 127519455-127591817 Predicted secreted proteins Evidence at protein level HPA036263, HPA041449 Supported Group enriched Group enriched 21 duodenum: 620.9;salivary gland: 164.6;stomach: 319.1 esophagus: 17.2 SLC6A19 ENSG00000174358 Solute carrier family 6 (neutral amino acid transporter), member 19 5 1201595-1225117 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA037415, HPA043207 Supported Renal cancer:4.14e-6 (favourable) Tissue enhanced Group enriched 21 duodenum: 143.3;kidney: 91.3;small intestine: 160.0 rectum: 6.3 ITLN2 HL-2 ENSG00000158764 Intelectin 2 1 160945025-160954799 Predicted secreted proteins Evidence at protein level HPA006683 Approved Tissue enhanced Group enriched 20 duodenum: 251.5;small intestine: 463.3 lung: 18.3 ASIC5 ACCN5, HINAC, INAC ENSG00000256394 Acid sensing (proton gated) ion channel family member 5 4 155829729-155866273 Predicted membrane proteins Evidence at protein level HPA014903, HPA029444 Approved Not detected Group enriched 19 duodenum: 2.4;small intestine: 1.3 all non-specific tissues: 0.0 ASAH2 ENSG00000188611 N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2 10 50182778-50248610 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA061171 Supported Approved Focal adhesion sites Mixed Group enriched 18 duodenum: 85.8;small intestine: 72.9 stomach: 4.4 MTTP ABL, MTP ENSG00000138823 Microsomal triglyceride transfer protein 4 99563761-99623999 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA051170, HPA054862 Uncertain Approved Cytosol Tissue enriched Group enriched 17 duodenum: 243.0;liver: 133.9;small intestine: 299.0 testis: 13.5 CLDN15 ENSG00000106404 Claudin 15 7 101232092-101238820 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level Renal cancer:5.31e-5 (unfavourable), Pancreatic cancer:2.56e-4 (favourable), Urothelial cancer:3.30e-4 (favourable) Expressed in all Group enriched 16 duodenum: 248.2;small intestine: 187.4 spleen: 13.5 SI ENSG00000090402 Sucrase-isomaltase (alpha-glucosidase) 3 164978898-165078495 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA011897 Supported Tissue enhanced Group enriched 15 duodenum: 562.3;small intestine: 503.3 rectum: 34.9 CEACAM18 ENSG00000213822 Carcinoembryonic antigen-related cell adhesion molecule 18 19 51478622-51490952 Predicted secreted proteins Evidence at protein level HPA059487 Uncertain Approved Midbody Tissue enhanced Group enriched 14 duodenum: 10.8;small intestine: 7.3 gallbladder: 0.6 CHST5 FLJ22167, I-GLCNAC-6-ST ENSG00000135702 Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 5 16 75528535-75535247 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA043804 Approved Group enriched Group enriched 14 colon: 46.8;duodenum: 88.4;rectum: 60.8;small intestine: 85.3 stomach: 4.9 GUCY2C GUC2C, STAR ENSG00000070019 Guanylate cyclase 2C 12 14612632-14696585 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA037655, HPA073759 Uncertain Uncertain Vesicles Liver cancer:1.37e-5 (unfavourable) Group enriched Group enriched 13 colon: 38.4;duodenum: 70.6;rectum: 48.1;small intestine: 74.7 appendix: 4.5 NAT2 AAC2 ENSG00000156006 N-acetyltransferase 2 (arylamine N-acetyltransferase) 8 18391245-18401218 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA043704 Uncertain Colorectal cancer:4.61e-5 (favourable) Tissue enhanced Group enriched 13 colon: 14.7;duodenum: 33.6;liver: 62.2;rectum: 14.2;small intestine: 27.7 smooth muscle: 2.3 NLRP6 CLR11.4, NALP6, PAN3, PYPAF5 ENSG00000174885 NLR family, pyrin domain containing 6 11 278365-285359 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA043681, HPA048500 Supported Liver cancer:4.23e-5 (favourable) Mixed Group enriched 13 duodenum: 40.5;small intestine: 41.0 appendix: 3.1 XPNPEP2 ENSG00000122121 X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-bound X 129738974-129769538 Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA000339, CAB025136, CAB025269 Supported Approved Golgi apparatus Group enriched Group enriched 13 duodenum: 131.6;kidney: 174.6;small intestine: 236.2 liver: 14.3 CDHR2 FLJ20124, FLJ20383, PC-LKC, PCDH24, PCLKC ENSG00000074276 Cadherin-related family member 2 5 176542511-176595974 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA012569, HPA017053 Supported Renal cancer:9.29e-4 (favourable) Group enriched Group enriched 12 duodenum: 284.1;small intestine: 265.8 colon: 23.1 FABP2 I-FABP ENSG00000145384 Fatty acid binding protein 2, intestinal 4 119317250-119322390 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA034607, CAB047325, CAB047326 Supported Approved Plasma membrane
Actin filaments
Cytosol Group enriched Group enriched 12 duodenum: 268.5;small intestine: 565.3 rectum: 34.6 MOGAT2 DGAT2L5, FLJ22644, MGAT2 ENSG00000166391 Monoacylglycerol O-acyltransferase 2 11 75717819-75732958 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA028834 Uncertain Tissue enhanced Group enriched 12 colon: 12.7;duodenum: 38.2;liver: 12.1;rectum: 12.7;small intestine: 44.5 appendix: 2.0 NR1I2 BXR, ONR1, PAR2, PXR, SXR ENSG00000144852 Nuclear receptor subfamily 1, group I, member 2 3 119780484-119818485 FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA029309, HPA055121, HPA073926 Validated Nucleoplasm Group enriched Group enriched 12 colon: 9.3;duodenum: 23.2;gallbladder: 6.0;liver: 19.7;rectum: 9.4;small intestine: 26.3 stomach: 1.3 SLC39A5 ENSG00000139540 Solute carrier family 39 (zinc transporter), member 5 12 56230049-56237846 Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA018423 Approved Nucleoplasm
Vesicles
Cytosol Renal cancer:5.05e-4 (favourable) Tissue enhanced Group enriched 12 colon: 74.5;duodenum: 247.0;kidney: 114.6;liver: 85.7;pancreas: 53.1;rectum: 49.7;small intestine: 245.4 gallbladder: 10.0 KHK ENSG00000138030 Ketohexokinase (fructokinase) 2 27086747-27100772 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA007040 Supported Approved Cytosol Endometrial cancer:7.62e-8 (unfavourable) Group enriched Group enriched 11 duodenum: 116.2;kidney: 111.0;liver: 97.3;small intestine: 135.8 cerebral cortex: 10.1 ABCC2 CMOAT, cMRP, DJS, MRP2 ENSG00000023839 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 10 99782732-99852192 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA004860, CAB037271 Approved Renal cancer:1.93e-5 (unfavourable) Tissue enhanced Group enriched 10 duodenum: 44.7;gallbladder: 42.8;kidney: 20.8;liver: 67.6;small intestine: 50.5 breast: 4.3 CHP2 ENSG00000166869 Calcineurin-like EF-hand protein 2 16 23754627-23758951 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB072806 Approved Tissue enhanced Group enriched 10 colon: 121.4;duodenum: 259.0;rectum: 130.7;skin: 144.2;small intestine: 232.0 cervix, uterine: 17.4 CYP2C18 CPCI, CYP2C, CYP2C17, P450IIC17 ENSG00000108242 Cytochrome P450, family 2, subfamily C, polypeptide 18 10 94683621-94736190 Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level Tissue enhanced Group enriched 10 duodenum: 105.9;esophagus: 24.7;gallbladder: 24.5;liver: 97.7;small intestine: 90.0;stomach: 62.7 tonsil: 6.4 HHLA2 B7-H5, B7H7, B7y ENSG00000114455 HERV-H LTR-associating 2 3 108296490-108378285 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA055478 Approved Group enriched Group enriched 10 colon: 89.3;duodenum: 89.6;gallbladder: 46.3;rectum: 92.1;small intestine: 146.8 stomach: 9.3 PLA2G12B PLA2G13 ENSG00000138308 Phospholipase A2, group XIIB 10 72935170-72954778 Plasma proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA057745, HPA059562 Approved Approved Vesicles Tissue enriched Group enriched 10 duodenum: 36.2;kidney: 18.9;liver: 49.8;small intestine: 46.9 lung: 3.9 SLC52A1 FLJ10060, GPCR42, GPR172B, hRFT1, PAR2, RFVT1 ENSG00000132517 Solute carrier family 52 (riboflavin transporter), member 1 17 5032600-5052009 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB011449 Uncertain Cervical cancer:9.54e-4 (favourable) Mixed Group enriched 10 duodenum: 37.1;placenta: 26.0;skin: 13.3;small intestine: 26.8 parathyroid gland: 2.6 SLC5A1 D22S675, NAGT, SGLT1 ENSG00000100170 Solute carrier family 5 (sodium/glucose cotransporter), member 1 22 32043032-32113029 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB015467, HPA051805, HPA055106 Supported Approved Nucleoplasm
Vesicles Renal cancer:6.97e-7 (favourable), Endometrial cancer:2.59e-4 (favourable) Mixed Group enriched 10 duodenum: 518.9;small intestine: 320.2 gallbladder: 40.3 SLC5A9 SGLT4 ENSG00000117834 Solute carrier family 5 (sodium/sugar cotransporter), member 9 1 48222685-48248644 Predicted membrane proteins, Transporters Evidence at protein level HPA050263 Approved Actin filaments
Cytosol Renal cancer:1.84e-5 (unfavourable) Tissue enhanced Group enriched 10 duodenum: 43.8;small intestine: 46.4 lung: 4.5 SLC6A4 5-HTT, HTT, OCD1, SERT1 ENSG00000108576 Solute carrier family 6 (neurotransmitter transporter), member 4 17 30194319-30236002 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA054723, HPA074728 Supported Supported Golgi apparatus
Vesicles Tissue enhanced Group enriched 10 duodenum: 10.7;lung: 44.2;placenta: 26.3;small intestine: 46.2 esophagus: 3.1 SLC7A9 CSNU3 ENSG00000021488 Solute carrier family 7 (amino acid transporter light chain, bo,+ system), member 9 19 32830509-32869766 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA042591 Supported Group enriched Group enriched 10 duodenum: 81.2;kidney: 69.6;small intestine: 125.7 liver: 8.9 ANPEP CD13, gp150, LAP1, p150, PEPN ENSG00000166825 Alanyl (membrane) aminopeptidase 15 89784889-89815401 CD markers, Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002417, HPA004625 Supported Supported Nucleus
Plasma membrane Expressed in all Group enriched 9 duodenum: 2451.4;small intestine: 2177.9 colon: 263.9 ATOH1 bHLHa14, HATH1, MATH-1, Math1 ENSG00000172238 Atonal bHLH transcription factor 1 4 93828753-93830964 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at transcript level Colorectal cancer:3.26e-5 (favourable) Tissue enhanced Group enriched 9 colon: 18.0;duodenum: 11.4;rectum: 20.1;small intestine: 22.8 appendix: 2.0 CDHR5 FLJ20219, MU-PCDH, MUCDHL, MUPCDH ENSG00000099834 Cadherin-related family member 5 11 616565-626078 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA009081, HPA009173, CAB025004 Supported Group enriched Group enriched 9 colon: 42.5;duodenum: 85.2;kidney: 23.4;liver: 20.6;rectum: 55.1;small intestine: 65.8 gallbladder: 5.3 CDX1 ENSG00000113722 Caudal type homeobox 1 5 150166795-150184558 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA055196 Supported Tissue enhanced Group enriched 9 colon: 132.2;duodenum: 66.3;rectum: 137.0;small intestine: 107.0 appendix: 12.7 CTSE ENSG00000196188 Cathepsin E 1 206009264-206023909 Enzymes, Predicted secreted proteins Evidence at protein level HPA012940, CAB032687 Supported Urothelial cancer:5.26e-5 (favourable) Group enriched Group enriched 9 duodenum: 235.5;stomach: 1126.5 lung: 74.6 REG1A PSP, PSPS, PSPS1, PTP, REG ENSG00000115386 Regenerating islet-derived 1 alpha 2 79120362-79123419 Plasma proteins, Predicted secreted proteins Evidence at protein level CAB025138, HPA045549, HPA045579 Supported Group enriched Group enriched 9 duodenum: 7327.1;pancreas: 10865.2;small intestine: 4712.3 stomach: 839.5 REG4 GISP, REG-IV, RELP ENSG00000134193 Regenerating islet-derived family, member 4 1 119794018-119811660 Predicted secreted proteins Evidence at protein level CAB025867, HPA046555 Supported Group enriched Group enriched 9 colon: 222.4;duodenum: 246.1;rectum: 304.0;small intestine: 676.7 appendix: 41.2 SLC2A7 GLUT7 ENSG00000197241 Solute carrier family 2 (facilitated glucose transporter), member 7 1 9003300-9026345 Predicted membrane proteins, Transporters Evidence at protein level HPA039931 Uncertain Not detected Group enriched 9 duodenum: 3.1;small intestine: 3.1 epididymis,testis: 0.3 SLC5A4 DJ90G24.4, SAAT1, SGLT3 ENSG00000100191 Solute carrier family 5 (glucose activated ion channel), member 4 22 32218476-32255341 Predicted membrane proteins, Transporters Evidence at transcript level Tissue enriched Group enriched 9 duodenum: 18.5;small intestine: 21.8 lung: 2.3 TMEM236 bA162I21.2, bA16O1.2, FAM23A, FAM23B ENSG00000148483 Transmembrane protein 236 10 17752252-17800868 Predicted membrane proteins Evidence at transcript level Tissue enhanced Group enriched 9 colon: 14.7;duodenum: 22.7;rectum: 15.8;small intestine: 38.4 appendix: 2.4 AQP10 ENSG00000143595 Aquaporin 10 1 154321090-154325325 Predicted membrane proteins, Transporters Evidence at protein level HPA065947 Supported Not detected Group enriched 8 duodenum: 70.3;small intestine: 50.1 fallopian tube: 7.1 CLCA1 CaCC, CLCRG1 ENSG00000016490 Chloride channel accessory 1 1 86468368-86500289 Predicted secreted proteins, Transporters Evidence at protein level HPA052787, HPA059301 Supported Colorectal cancer:2.98e-4 (favourable) Group enriched Group enriched 8 colon: 713.1;duodenum: 906.3;rectum: 1141.9;small intestine: 1551.5 appendix: 139.7 CLRN3 MGC32871, TMEM12, USH3AL1 ENSG00000180745 Clarin 3 10 127877841-127892947 Predicted membrane proteins, Transporters Evidence at protein level HPA014482 Approved Stomach cancer:8.98e-4 (favourable) Group enriched Group enriched 8 colon: 71.2;duodenum: 75.4;gallbladder: 23.7;kidney: 43.9;liver: 40.2;rectum: 77.5;small intestine: 99.5 appendix: 7.5 DHRS11 MGC4172, SDR24C1 ENSG00000278535 Dehydrogenase/reductase (SDR family) member 11 17 36591798-36600806 Predicted intracellular proteins Evidence at protein level HPA041226, HPA048236, HPA053623 Supported Approved Golgi apparatus
Cytosol Renal cancer:3.24e-4 (favourable) Expressed in all Group enriched 8 colon: 45.4;duodenum: 153.7;rectum: 47.9;small intestine: 136.4 testis: 11.8 GPA33 A33 ENSG00000143167 Glycoprotein A33 (transmembrane) 1 167052836-167166479 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018858, CAB025943 Supported Tissue enriched Group enriched 8 colon: 186.8;duodenum: 134.3;rectum: 191.4;small intestine: 133.9 appendix: 19.9 HTR1D 5-HT1D, HT1DA, HTRL, RDC4 ENSG00000179546 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled 1 23191895-23194729 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Liver cancer:1.86e-4 (unfavourable), Pancreatic cancer:5.30e-4 (unfavourable) Mixed Group enriched 8 duodenum: 9.7;gallbladder: 2.5;small intestine: 9.3 fallopian tube: 0.8 LRRC19 FLJ21302 ENSG00000184434 Leucine rich repeat containing 19 9 26993136-27005693 Predicted membrane proteins Evidence at protein level Renal cancer:7.08e-8 (favourable) Group enriched Group enriched 8 colon: 36.8;duodenum: 24.4;gallbladder: 9.5;kidney: 45.4;rectum: 36.2;small intestine: 35.4 appendix: 3.7 MALRD1 bA265G8.2, C10orf112, Diet1 ENSG00000204740 MAM and LDL receptor class A domain containing 1 10 19048771-19790401 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035732, HPA038106, HPA046848 Uncertain Validated Golgi apparatus Tissue enhanced Group enriched 8 duodenum: 32.2;small intestine: 35.1 testis: 4.4 MUC17 ENSG00000169876 Mucin 17, cell surface associated 7 101020072-101058745 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA031634 Supported Group enriched Group enriched 8 duodenum: 22.4;small intestine: 43.3 rectum: 3.9 REEP6 C19orf32, DP1L1, FLJ25383 ENSG00000115255 Receptor accessory protein 6 19 1490747-1497927 Predicted membrane proteins Evidence at protein level HPA003895, HPA048015 Approved Supported Endoplasmic reticulum Expressed in all Group enriched 8 adrenal gland: 48.4;duodenum: 170.8;liver: 76.3;small intestine: 170.5;testis: 181.6 prostate: 17.0 SLC35G1 C10orf60, FLJ33990, TMEM20 ENSG00000176273 Solute carrier family 35, member G1 10 93893973-93956062 Predicted membrane proteins, Transporters Evidence at protein level Mixed Group enriched 8 duodenum: 88.4;small intestine: 45.8 rectum: 7.9 SLC39A4 AEZ, AWMS2, ZIP4 ENSG00000147804 Solute carrier family 39 (zinc transporter), member 4 8 144409742-144416895 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Renal cancer:9.04e-4 (favourable) Expressed in all Group enriched 8 duodenum: 138.0;small intestine: 97.8 kidney: 14.3 SMIM24 C19orf77, HSPC323 ENSG00000095932 Small integral membrane protein 24 19 3473986-3480542 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045046, HPA056027 Supported Approved Nucleoplasm
Cytosol Renal cancer:4.13e-10 (favourable) Tissue enhanced Group enriched 8 duodenum: 780.7;epididymis: 1898.5;kidney: 832.6;small intestine: 696.9 stomach: 139.3 ASPDH ENSG00000204653 Aspartate dehydrogenase domain containing 19 50511600-50514690 Enzymes, Predicted intracellular proteins Evidence at protein level HPA042631, HPA042654 Approved Tissue enriched Group enriched 7 cerebral cortex: 17.9;duodenum: 7.1;kidney: 27.9;liver: 34.6 adrenal gland: 3.3 C11orf86 FLJ22675 ENSG00000173237 Chromosome 11 open reading frame 86 11 66975277-66977004 Predicted intracellular proteins Evidence at transcript level HPA039348 Uncertain Renal cancer:1.02e-5 (unfavourable), Pancreatic cancer:6.97e-5 (unfavourable), Lung cancer:8.97e-4 (unfavourable) Mixed Group enriched 7 duodenum: 70.2;small intestine: 72.4 colon: 10.4 CDH17 cadherin, HPT-1 ENSG00000079112 Cadherin 17, LI cadherin (liver-intestine) 8 94127171-94217303 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA023614, HPA023616, CAB025143, HPA026556 Supported Supported Cell Junctions Group enriched Group enriched 7 colon: 261.7;duodenum: 323.0;rectum: 272.5;small intestine: 300.5 appendix: 39.2 FABP1 L-FABP ENSG00000163586 Fatty acid binding protein 1, liver 2 88122982-88128116 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002305, HPA028275 Supported Approved Nucleoplasm
Cytosol Group enriched Group enriched 7 colon: 4641.2;duodenum: 4243.6;liver: 5656.0;rectum: 3161.5;small intestine: 4603.3 kidney: 599.7 GALNT8 GALNAC-T8 ENSG00000130035 Polypeptide N-acetylgalactosaminyltransferase 8 12 4720341-4851927 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012638, HPA014418, HPA073461 Approved Approved Vesicles Tissue enhanced Group enriched 7 cerebral cortex: 19.5;colon: 18.0;duodenum: 8.4;rectum: 41.3;small intestine: 19.3;testis: 26.3 appendix: 3.3 HAPLN4 BRAL2, KIAA1926 ENSG00000187664 Hyaluronan and proteoglycan link protein 4 19 19255641-19262796 Predicted secreted proteins Evidence at protein level HPA055856 Approved Not detected Group enriched 7 cerebral cortex: 8.5;duodenum: 15.7;small intestine: 21.7 cervix, uterine: 2.1 HNF4A HNF4, MODY, MODY1, NR2A1, TCF14 ENSG00000101076 Hepatocyte nuclear factor 4, alpha 20 44355700-44434596 Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA004712, CAB019417 Supported Supported Nucleoplasm Tissue enhanced Group enriched 7 colon: 58.9;duodenum: 105.9;kidney: 44.3;liver: 50.9;rectum: 48.5;small intestine: 92.8;stomach: 22.1 gallbladder: 9.2 IGSF23 ENSG00000216588 Immunoglobulin superfamily, member 23 19 44613630-44636781 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA051811, HPA054591 Uncertain Approved Nucleus
Cell Junctions Liver cancer:7.20e-6 (favourable) Tissue enriched Group enriched 7 duodenum: 15.6;liver: 13.1;small intestine: 17.8 testis: 2.3 NEU4 ENSG00000204099 Sialidase 4 2 241808825-241817413 Enzymes, Predicted intracellular proteins Evidence at protein level HPA037394, HPA037395 Uncertain Group enriched Group enriched 7 bone marrow: 2.4;cerebral cortex: 6.4;colon: 8.5;duodenum: 5.7;liver: 4.1;rectum: 3.9;small intestine: 5.4 gallbladder: 0.8 PHGR1 ENSG00000233041 Proline/histidine/glycine-rich 1 15 40351033-40356434 Predicted intracellular proteins Evidence at protein level HPA068787 Supported Approved Vesicles Breast cancer:2.05e-4 (favourable) Group enriched Group enriched 7 colon: 1475.8;duodenum: 917.9;rectum: 408.6;small intestine: 1813.6 stomach: 170.7 PPP1R14D CPI17-like, FLJ20251, GBPI-1, MGC119014, MGC119016 ENSG00000166143 Protein phosphatase 1, regulatory (inhibitor) subunit 14D 15 40815445-40828709 Predicted intracellular proteins Evidence at protein level HPA041846 Uncertain Renal cancer:3.07e-4 (unfavourable) Tissue enhanced Group enriched 7 colon: 107.5;duodenum: 114.3;gallbladder: 24.3;rectum: 101.6;small intestine: 91.7 appendix: 12.9 SH2D7 LOC646892 ENSG00000183476 SH2 domain containing 7 15 78077808-78104909 Predicted intracellular proteins Evidence at transcript level HPA051320 Approved Mixed Group enriched 7 colon: 1.7;duodenum: 2.2;small intestine: 1.9;testis: 5.7 cerebral cortex,rectum: 0.4 SULT1E1 EST, STE ENSG00000109193 Sulfotransferase family 1E, estrogen-preferring, member 1 4 69810780-69860152 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA028213, HPA028728, CAB047344 Supported Cervical cancer:4.06e-4 (favourable) Mixed Group enriched 7 duodenum: 28.4;liver: 18.7;skin: 7.6;small intestine: 30.3 adrenal gland: 3.1 TMEM253 C14orf176, C14orf95, NCRNA00220 ENSG00000232070 Transmembrane protein 253 14 21098937-21103724 Predicted membrane proteins Evidence at protein level HPA052329, HPA065092 Supported Mixed Group enriched 7 duodenum: 104.1;small intestine: 102.1 colon: 15.8 UGT1A5 UGT1E ENSG00000240224 UDP glucuronosyltransferase 1 family, polypeptide A5 2 233712992-233773299 Enzymes, Predicted membrane proteins Evidence at transcript level Not detected Group enriched 7 duodenum: 7.7;gallbladder: 3.9;small intestine: 6.9 liver: 0.9 VIL1 D2S1471, VIL ENSG00000127831 Villin 1 2 218419092-218453295 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002452, HPA006884, HPA006885 Supported Supported Plasma membrane Tissue enhanced Group enriched 7 colon: 175.1;duodenum: 409.9;rectum: 199.9;small intestine: 489.9 gallbladder: 44.9 ZNF488 FLJ32104 ENSG00000265763 Zinc finger protein 488 10 47365496-47384273 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA035957, HPA035958, HPA044867 Uncertain Supported Nucleoplasm
Cytosol Pancreatic cancer:4.02e-7 (unfavourable) Mixed Group enriched 7 cerebral cortex: 19.1;duodenum: 23.2;placenta: 4.7;small intestine: 12.4 skin: 2.0 ACE2 ENSG00000130234 Angiotensin I converting enzyme 2 X 15561033-15602148 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA000288, CAB026174 Supported Renal cancer:2.12e-5 (favourable), Liver cancer:4.21e-4 (favourable) Tissue enhanced Group enriched 6 duodenum: 186.1;gallbladder: 100.6;kidney: 93.3;small intestine: 266.6;testis: 92.6 heart muscle: 23.1 ACY1 ENSG00000243989 Aminoacylase 1 3 51983340-51989197 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB003695, HPA036174, HPA036175 Supported Renal cancer:2.93e-4 (favourable), Urothelial cancer:6.77e-4 (favourable) Expressed in all Group enriched 6 duodenum: 182.6;kidney: 462.6;liver: 146.9;small intestine: 158.4 thyroid gland: 40.0 ADGRG7 FLJ14454, GPR128 ENSG00000144820 Adhesion G protein-coupled receptor G7 3 100609589-100695479 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Tissue enhanced Group enriched 6 duodenum: 44.0;liver: 12.4;small intestine: 43.8 colon: 5.4 AMN amnionless ENSG00000166126 Amnion associated transmembrane protein 14 102922656-102933596 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000817 Approved Renal cancer:9.62e-5 (favourable) Mixed Group enriched 6 colon: 20.4;duodenum: 35.1;kidney: 29.0;small intestine: 72.0 liver,stomach: 6.8 BTNL8 BTN9.2, FLJ21458 ENSG00000113303 Butyrophilin-like 8 5 180899077-180950906 Predicted membrane proteins Evidence at protein level HPA039738 Approved Group enriched Group enriched 6 colon: 26.5;duodenum: 120.7;rectum: 28.2;small intestine: 96.1 gallbladder: 10.5 C8G ENSG00000176919 Complement component 8, gamma polypeptide 9 136945246-136946974 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA046269 Approved Uncertain Endoplasmic reticulum Colorectal cancer:2.99e-4 (unfavourable) Tissue enriched Group enriched 6 duodenum: 51.3;liver: 106.1;small intestine: 35.3 gallbladder: 9.9 CASP5 ICE(rel)III ENSG00000137757 Caspase 5, apoptosis-related cysteine peptidase 11 104994235-105023168 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA040937 Uncertain Group enriched Group enriched 6 appendix: 20.7;colon: 16.2;duodenum: 10.4;rectum: 14.7;small intestine: 19.3 smooth muscle: 2.6 CCR9 CDw199, GPR-9-6, GPR28 ENSG00000173585 Chemokine (C-C motif) receptor 9 3 45886504-45903177 CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB006839 Uncertain Not detected Group enriched 6 appendix: 1.5;duodenum: 3.9;small intestine: 5.8;spleen: 1.2 lymph node: 0.5 CDX2 CDX3 ENSG00000165556 Caudal type homeobox 2 13 27962137-27971139 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002221, HPA045669, HPA049580 Supported Supported Nucleoplasm Tissue enriched Group enriched 6 colon: 31.4;duodenum: 22.9;rectum: 25.3;small intestine: 30.8 appendix: 4.9 CYP4F2 ENSG00000186115 Cytochrome P450, family 4, subfamily F, polypeptide 2 19 15878023-15898120 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA014048, HPA017265, HPA058960 Supported Tissue enriched Group enriched 6 duodenum: 80.4;epididymis: 27.5;kidney: 39.1;liver: 84.6;small intestine: 86.1 prostate: 10.6 EFNA2 ELF-1, EPLG6, LERK6 ENSG00000099617 Ephrin-A2 19 1286154-1300237 Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005178 Uncertain Tissue enhanced Group enriched 6 colon: 7.1;duodenum: 8.2;small intestine: 10.8 rectum: 1.5 EPS8L3 FLJ21522, MGC16817 ENSG00000198758 EPS8-like 3 1 109750080-109764027 Predicted intracellular proteins Evidence at protein level HPA030998 Approved Approved Vesicles Renal cancer:2.52e-5 (unfavourable), Liver cancer:4.13e-5 (unfavourable), Urothelial cancer:1.82e-4 (favourable) Group enriched Group enriched 6 colon: 76.3;duodenum: 156.3;gallbladder: 60.0;rectum: 87.4;small intestine: 170.4;stomach: 54.0 appendix: 15.8 ERN2 IRE1b ENSG00000134398 Endoplasmic reticulum to nucleus signaling 2 16 23690309-23713500 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA016558 Uncertain Mixed Group enriched 6 cervix, uterine: 26.7;colon: 27.8;duodenum: 12.7;gallbladder: 25.2;rectum: 23.4;small intestine: 10.1;stomach: 49.9 appendix: 3.9 FOLH1 FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA ENSG00000086205 Folate hydrolase (prostate-specific membrane antigen) 1 11 49146635-49208670 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB001451, HPA010593 Supported Renal cancer:1.30e-6 (unfavourable), Endometrial cancer:5.24e-5 (favourable), Liver cancer:4.25e-4 (favourable) Tissue enriched Group enriched 6 duodenum: 307.0;prostate: 128.9;small intestine: 93.5 cerebral cortex: 31.1 IHH BDA1, HHG2 ENSG00000163501 Indian hedgehog 2 219054420-219060467 Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Endometrial cancer:3.67e-6 (favourable) Tissue enhanced Group enriched 6 cervix, uterine: 8.8;colon: 21.4;duodenum: 15.3;endometrium: 31.4;rectum: 16.9;small intestine: 16.8;stomach: 15.6 appendix,prostate: 3.1 MISP C19orf21, Caprice, DKFZp686H18209 ENSG00000099812 Mitotic spindle positioning 19 751126-764318 Predicted intracellular proteins Evidence at protein level HPA049511, HPA062232 Supported Validated Plasma membrane
Focal adhesion sites Tissue enhanced Group enriched 6 colon: 96.4;duodenum: 178.1;rectum: 53.5;small intestine: 221.5 stomach: 22.1 MOGAT3 DC7, MGAT3 ENSG00000106384 Monoacylglycerol O-acyltransferase 3 7 101195007-101201021 Enzymes, Predicted membrane proteins Evidence at protein level HPA011940 Uncertain Approved Centrosome Tissue enhanced Group enriched 6 colon: 11.5;duodenum: 31.2;rectum: 12.0;small intestine: 34.2 liver: 3.4 MUC13 DRCC1 ENSG00000173702 Mucin 13, cell surface associated 3 124905442-124953819 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA045163 Supported Renal cancer:9.73e-5 (unfavourable) Tissue enhanced Group enriched 6 colon: 307.7;duodenum: 631.7;rectum: 335.1;small intestine: 567.0 appendix: 82.8 MYRFL bcm1377, C12orf15, C12orf28, FLJ25056 ENSG00000166268 Myelin regulatory factor-like 12 69825304-69959097 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA049340 Approved Approved Nucleoli Mixed Group enriched 6 duodenum: 24.4;small intestine: 24.5 testis: 4.3 PCK2 PEPCK, PEPCK2 ENSG00000100889 Phosphoenolpyruvate carboxykinase 2 (mitochondrial) 14 24094053-24110598 Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB018734, HPA051162, HPA053502 Supported Validated Mitochondria Liver cancer:2.81e-4 (favourable) Expressed in all Group enriched 6 duodenum: 377.7;kidney: 191.6;liver: 258.5;small intestine: 282.4 colon: 47.9 PRAP1 UPA ENSG00000165828 Proline-rich acidic protein 1 10 133309410-133352683 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA035360, HPA038713, HPA052451 Supported Approved Nucleoplasm
Vesicles
Plasma membrane Group enriched Group enriched 6 duodenum: 981.7;liver: 306.9;small intestine: 1145.9 kidney: 136.1 SCT ENSG00000070031 Secretin 11 626431-627143 Predicted secreted proteins Evidence at protein level HPA050961 Supported Colorectal cancer:3.70e-4 (unfavourable) Mixed Group enriched 6 duodenum: 35.9;small intestine: 8.0 spleen: 3.5 SLC17A4 KIAA2138 ENSG00000146039 Solute carrier family 17, member 4 6 25754699-25781191 Predicted membrane proteins, Transporters Evidence at transcript level HPA055564 Approved Group enriched Group enriched 6 colon: 20.8;duodenum: 29.4;gallbladder: 25.5;liver: 22.4;rectum: 29.4;small intestine: 35.7 pancreas: 4.2 SLC5A11 KST1, SGLT6, SMIT2 ENSG00000158865 Solute carrier family 5 (sodium/inositol cotransporter), member 11 16 24845841-24911628 Predicted membrane proteins Evidence at protein level HPA035331 Uncertain Approved Nucleus
Cytosol Mixed Group enriched 6 cerebral cortex: 10.5;duodenum: 6.8;kidney: 6.0;small intestine: 15.5 breast: 1.7 SPINK4 MGC133107, PEC-60 ENSG00000122711 Serine peptidase inhibitor, Kazal type 4 9 33218365-33248567 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA007286 Supported Approved Nucleus
Golgi apparatus
Vesicles Colorectal cancer:8.85e-5 (favourable) Group enriched Group enriched 6 colon: 647.7;duodenum: 273.9;rectum: 1085.3;small intestine: 748.6 appendix: 112.0 TPH1 TPH, TPRH ENSG00000129167 Tryptophan hydroxylase 1 11 18017564-18042426 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB010767, HPA022483 Supported Uncertain Cytosol Mixed Group enriched 6 colon: 9.0;duodenum: 10.5;rectum: 21.3;small intestine: 12.9;stomach: 15.5 prostate: 2.2 UGT2B15 UGT2B8 ENSG00000196620 UDP glucuronosyltransferase 2 family, polypeptide B15 4 68537413-68670628 Enzymes, Predicted membrane proteins Evidence at protein level HPA045108 Approved Urothelial cancer:4.50e-4 (favourable), Liver cancer:9.82e-4 (favourable) Tissue enriched Group enriched 6 colon: 23.8;duodenum: 30.6;gallbladder: 114.5;liver: 108.6;small intestine: 33.9 stomach: 10.2 AADAC CES5A1, DAC ENSG00000114771 Arylacetamide deacetylase 3 151814037-151828488 Enzymes, Predicted intracellular proteins Evidence at protein level HPA002911 Approved Ovarian cancer:5.58e-6 (favourable), Stomach cancer:2.19e-4 (unfavourable), Pancreatic cancer:5.02e-4 (unfavourable) Tissue enriched Group enriched 5 adrenal gland: 151.1;duodenum: 187.8;liver: 385.8;small intestine: 220.5 stomach: 43.9 AC004754.3 ENSG00000269881 16 249547-269943 Predicted membrane proteins Evidence at transcript level HPA011651 Uncertain Nucleoplasm
Mitochondria Not detected Group enriched 5 duodenum: 14.6;small intestine: 8.1 testis: 2.0 ANXA13 ANX13 ENSG00000104537 Annexin A13 8 123680794-123737407 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA018535, HPA019569, HPA019650, CAB025135 Supported Supported Plasma membrane Group enriched Group enriched 5 duodenum: 304.7;fallopian tube: 91.6;gallbladder: 228.3;small intestine: 240.9 rectum: 39.8 B3GALT5 B3GalT-V, B3T5, beta3Gal-T5, GLCT5 ENSG00000183778 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 21 39556442-39673137 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA054092, HPA054684 Approved Endometrial cancer:6.36e-4 (favourable) Mixed Group enriched 5 colon: 23.1;duodenum: 28.2;gallbladder: 8.6;rectum: 41.3;small intestine: 37.9 stomach: 5.1 CCK ENSG00000187094 Cholecystokinin 3 42257825-42266207 Plasma proteins, Predicted secreted proteins Evidence at protein level CAB002308, HPA045039 Supported Supported Group enriched Group enriched 5 cerebral cortex: 134.1;duodenum: 119.6;prostate: 32.8 small intestine: 18.1 ENPEP CD249, gp160 ENSG00000138792 Glutamyl aminopeptidase (aminopeptidase A) 4 110365733-110565285 CD markers, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA005128 Approved Tissue enriched Group enriched 5 duodenum: 37.5;kidney: 93.6;parathyroid gland: 157.9;small intestine: 183.8 placenta: 21.5 FOXA3 HNF3G ENSG00000170608 Forkhead box A3 19 45863989-45873797 Predicted intracellular proteins, Transcription factors Evidence at protein level CAB015154, HPA054034 Uncertain Approved Nucleoplasm Mixed Group enriched 5 colon: 17.0;duodenum: 10.6;liver: 32.5;pancreas: 9.8;rectum: 18.2;small intestine: 14.2;stomach: 34.1 gallbladder: 3.6 HNF4G NR2A2 ENSG00000164749 Hepatocyte nuclear factor 4, gamma 8 75407914-75566843 Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA005438, HPA010610 Supported Approved Nucleoplasm
Cytosol Mixed Group enriched 5 duodenum: 103.0;small intestine: 128.1 rectum: 21.4 IL22RA1 CRF2-9, IL22R ENSG00000142677 Interleukin 22 receptor, alpha 1 1 24119771-24143121 Predicted membrane proteins Evidence at protein level HPA042399 Approved Mixed Group enriched 5 colon: 11.5;duodenum: 20.8;esophagus: 10.2;pancreas: 26.0;rectum: 11.1;skin: 38.8;small intestine: 32.0 gallbladder: 4.0 LRRC31 FLJ23259 ENSG00000114248 Leucine rich repeat containing 31 3 169839179-169869930 Predicted intracellular proteins Evidence at protein level HPA037548 Uncertain Mixed Group enriched 5 colon: 18.5;duodenum: 9.1;rectum: 24.7;small intestine: 11.2;stomach: 9.8 liver: 2.8 MGAM2 ENSG00000257743 Maltase-glucoamylase 2 (putative) 7 142111749-142222324 Enzymes, Predicted membrane proteins Evidence at protein level HPA055697 Supported Approved Vesicles
Cytosol Group enriched Group enriched 5 duodenum: 12.2;small intestine: 10.6 salivary gland: 2.1 NOS2 HEP-NOS, iNOS, NOS, NOS2A ENSG00000007171 Nitric oxide synthase 2, inducible 17 27756766-27800499 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002014 Approved Tissue enhanced Group enriched 5 appendix: 19.6;colon: 7.2;duodenum: 12.6;rectum: 10.0;small intestine: 24.6;urinary bladder: 6.7 smooth muscle: 2.5 RP11-407N17.3 ENSG00000258941 14 39233902-39350423 Predicted membrane proteins Evidence at protein level HPA000387, HPA000922, HPA054066, HPA055459 Uncertain Approved Endoplasmic reticulum Not detected Group enriched 5 duodenum: 16.1;kidney: 10.3;liver: 13.3;parathyroid gland: 21.0;small intestine: 19.1 gallbladder: 3.0 SLC15A1 HPECT1, HPEPT1, PEPT1 ENSG00000088386 Solute carrier family 15 (oligopeptide transporter), member 1 13 98683801-98752654 Predicted membrane proteins, Transporters Evidence at protein level HPA002827 Uncertain Approved Nucleoplasm
Cytosol Mixed Group enriched 5 duodenum: 157.7;gallbladder: 68.0;small intestine: 230.1 skin: 27.9 SLC23A1 SLC23A2, SVCT1, YSPL3 ENSG00000170482 Solute carrier family 23 (ascorbic acid transporter), member 1 5 139367196-139384553 Predicted membrane proteins, Transporters Evidence at protein level HPA047612 Supported Group enriched Group enriched 5 duodenum: 27.5;fallopian tube: 85.7;kidney: 41.7;small intestine: 73.4 liver: 10.7 SMLR1 ENSG00000256162 Small leucine-rich protein 1 6 130827406-130837135 Predicted membrane proteins Evidence at protein level HPA066060 Uncertain Tissue enriched Group enriched 5 duodenum: 12.5;liver: 28.9;small intestine: 11.6 kidney: 3.2 SULT1B1 ST1B2 ENSG00000173597 Sulfotransferase family, cytosolic, 1B, member 1 4 69721162-69787961 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002107 Supported Approved Nucleoplasm
Golgi apparatus Group enriched Group enriched 5 colon: 70.7;duodenum: 101.9;rectum: 69.5;small intestine: 106.2;stomach: 41.6 appendix: 14.6 TM4SF5 ENSG00000142484 Transmembrane 4 L six family member 5 17 4771884-4783213 Predicted membrane proteins Evidence at protein level HPA055674 Uncertain Nucleoplasm
Plasma membrane
Cell Junctions Tissue enriched Group enriched 5 duodenum: 181.8;small intestine: 172.8 liver: 33.2 TM6SF2 Lpr4 ENSG00000213996 Transmembrane 6 superfamily member 2 19 19264364-19273391 Predicted membrane proteins Evidence at protein level HPA066026 Uncertain Tissue enhanced Group enriched 5 duodenum: 79.1;small intestine: 78.4 liver: 14.6 TMEM132E DFNB99 ENSG00000181291 Transmembrane protein 132E 17 34580749-34639318 Disease related genes, Predicted membrane proteins Evidence at protein level HPA070608 Approved Renal cancer:1.55e-4 (unfavourable) Group enriched Group enriched 5 cerebral cortex: 4.8;duodenum: 1.7;kidney: 3.2;small intestine: 1.1;testis: 1.5 cervix, uterine: 0.4 TRPM5 LTRPC5, MTR1 ENSG00000070985 Transient receptor potential cation channel, subfamily M, member 5 11 2404515-2423045 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA042115, HPA043315 Approved Tissue enhanced Group enriched 5 colon: 1.0;duodenum: 3.0;epididymis: 2.2;seminal vesicle: 2.5;small intestine: 2.9 testis,thyroid gland: 0.4 URAD PRHOXNB ENSG00000183463 Ureidoimidazoline (2-oxo-4-hydroxy-4-carboxy-5-) decarboxylase 13 27977714-27988654 Enzymes, Predicted intracellular proteins Evidence at transcript level HPA038972 Uncertain Tissue enriched Group enriched 5 colon: 13.0;duodenum: 8.5;small intestine: 18.3 appendix: 2.4 VNN1 Tiff66 ENSG00000112299 Vanin 1 6 132681590-132714049 Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA064145 Approved Renal cancer:2.52e-4 (unfavourable) Tissue enhanced Group enriched 5 duodenum: 176.1;gallbladder: 175.5;liver: 142.6;small intestine: 108.8 kidney: 27.4 WNT3 INT4, MGC131950, MGC138321, MGC138323 ENSG00000108379 Wingless-type MMTV integration site family, member 3 17 46762506-46833154 Disease related genes, Predicted secreted proteins Evidence at protein level HPA066281 Approved Vesicles Tissue enriched Group enriched 5 duodenum: 2.3;parathyroid gland: 2.3;skin: 9.2 cerebral cortex: 0.9